{
    "organizations": [],
    "uuid": "5d0030be3ac1a3c029395d588186e4995b4aa775",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/novartis-avexis/novartis-shells-out-8-7-bln-to-buy-avexis-idUSFWN1RM02T",
    "ord_in_thread": 0,
    "title": "Novartis shells out $8.7 bln to buy AveXis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "ZURICH, April 9 (Reuters) - Novartis said on Monday it plans to buy AveXis for $218 per share in a cash deal totaling $8.7 billion as the Swiss drugmaker adds a company whose top drug hopeful, for spinal muscular atrophy, has U.S. breakthrough therapy designation.\nNovartis is flush with cash, having just agreed to sell its stake in a consumer healthcare joint venture for $13 billion to GlaxoSmithKline. (Reporting by)\n ",
    "published": "2018-04-09T12:59:00.000+03:00",
    "crawled": "2018-04-10T12:35:07.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "zurich",
        "april",
        "reuters",
        "novartis",
        "said",
        "monday",
        "plan",
        "buy",
        "avexis",
        "per",
        "share",
        "cash",
        "deal",
        "totaling",
        "billion",
        "swiss",
        "drugmaker",
        "add",
        "company",
        "whose",
        "top",
        "drug",
        "hopeful",
        "spinal",
        "muscular",
        "atrophy",
        "breakthrough",
        "therapy",
        "designation",
        "novartis",
        "flush",
        "cash",
        "agreed",
        "sell",
        "stake",
        "consumer",
        "healthcare",
        "joint",
        "venture",
        "billion",
        "glaxosmithkline",
        "reporting"
    ]
}